Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis.
Hossein AzadehReza Alizadeh-NavaeiAlireza RezaiemaneshMisagh RajabinejadPublished in: Inflammopharmacology (2022)
The most common immune system-related AEs in patients treated with IL-17 inhibitors are mucosal and opportunistic infections.